• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Type 2 Diabetes: After the Diagnosis, Resist Inertia

Slideshow

Diabetes is a progressive disease and takes advantage of inaction. How would you manage our patient Mrs Davis?

After a diagnosis of type 2 diabetes, clinician and patient alike are challenged to keep pace with and, ideally stay ahead of, the progressive ß-cell deterioration that underlies diabetes pathophysiology. Find out how Mrs Davis and her doctor get started.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
ACP issues guidelines on newer pharmacologic treatment for adults with type 2 diabetes/ image credit: medication pens:©felipecaparros/stock.adobe.com

ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes

April 22nd 2024
Article

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose / image credit: ©New Africa/AdobeStock

Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose

April 15th 2024
Article

Your daily dose of the clinical news you may have missed.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age / image credit weightloss: ©CLIPAREA/shutterstock.com

Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests

April 5th 2024
Article

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose / image credit: ©New Africa/AdobeStock

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose

April 4th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.